DTX3L and diffuse large B-cell lymphoma: It remains to be investigated whether constitutive overexpression and/or phosphorylation of STAT1 alone, independent of ARTD9 or DTX3L, may also serve as novel useful prognostic biomarker for poor survival of fatal high-risk relapsed/refractory DLBCL.